Abstract: The present application discloses methods and uses for preparation of a dry solid composition as a precursor for a stable gel body formation upon addition of water. The invention also discloses the compositions obtained from said methods and uses. Said gel bodies can, for example, be used in pharmaceutical compositions to administer drug substances to patients with difficulties to swallow.

Abstract: The present invention relates to compounds of formula (I), wherein R1 to R5, T and L are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.

Abstract: The present invention relates to a method of treating an anaplastic lymphoma kinase (ALK) fusion-positive solid tumour or central nervous system tumour, comprising administering to a subject in need of such treatment a therapeutically effective amount of alectinib, or a pharmaceutically acceptable salt thereof, wherein the subject is aged <18 years.

Abstract: Provided herein are methods for assessing splice-switching ASOs using a reporter to detect splicing of a cryptic sequence located in the reporter pre-mRNA.

Abstract: The subject matter described herein is directed to methods of preparing compounds of general Formula I: or a salt or solvate thereof.

Abstract: The present invention relates to a method for the generation of single stranded DNA (ssDNA) molecules from circular double stranded DNA (dsDNA) molecules.

Abstract: The present invention relates to systems and methods in the field of digital pathology. It is particularly, but not exclusively, concerned with systems and methods for detecting brain lesions, and in particular brain metastases, in brain digital images.

Abstract: Disclosed herein are pharmaceutical compositions and dosage forms including N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino) benzamide that are useful in the treatment of subjects having cancer. The present disclosure also provides methods for preparing these pharmaceutical compositions and dosage forms, and methods of treating subjects having cancer utilizing the pharmaceutical compositions and dosage forms provided herein.

Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein X, Y, Z, A, L, B, and R1 to R3 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

Abstract: This invention relates to a new medical use for certain chemical compounds and pharmaceutical compositions containing them. The invention relates to compounds which are mGlu2/3 negative allosteric modulators for use in the treatment of intellectual disabilities. In another aspect, the invention relates to a pharmaceutical composition for use in the treatment of intellectual disabilities comprising a compound according to the invention and a pharmaceutically acceptable carrier.

Abstract: The present invention relates to compounds of formula (I), wherein R1 to R3, X, Y, A and W are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.

Abstract: The present invention relates to anti-C3bBb antibodies and methods of using the same.

Abstract: Systems and methods disclosed herein relate generally to systems and methods for detection, segmentation and characterization of isolated or overlapping object instances in digital images, applicable for detection, segmentation and characterization of crypts in histological images from patients with gastrointestinal disorders.

Abstract: The present invention relates to a process for synthesizing large scale a compound of formula (I), or pharmaceutically acceptable salt thereof, which is useful as the key intermediate for the synthesis of compounds for prophylaxis and treatment of a disease associated with the deposition of ?-amyloid in the brain, in particular Alzheimer's disease, and other diseases such as cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica and Down syndrome.

Abstract: The present invention relates to combination therapies employing PD-1 axis binding antagonists and LRRK2 inhibitors and, and the use of these combination therapies for the treatment of cancer.

Abstract: A virtual reality system for quantifying functional visual capabilities of a user at varying assessment conditions (e.g., varying light, contrast, color conditions), using a head-mountable display. In addition to the high relevance to users with optical conditions, the present embodiments can lead to rapid and simple measurements within the controlled and reproducible testing conditions that virtual reality can offer. The virtual environment system can obtain a selection of a task to be performed. During execution of the task, a virtual environment optical setting (e.g., a modified lighting setting in the virtual environment display) can be dynamically modified. The user can interact with the objects during execution of the task, which can provide an insight into functional visual capabilities of the user. After completion of the task, an output can be generated that quantifies a functional visual capability of the user during execution of the task.

Abstract: The present invention relates to a tablet comprising 6-((5-methyl-3-(6-methylpyridin-3-yl)isoxazol-4-yl)methoxy)-N-(tetrahydropyran-4-yl)pyridazine-3-carboxamide, to processes for its preparation, kits comprising it, and its use in medical treatment.

Abstract: The present disclosure relates to the fields of molecular biology, more specifically cytokine receptors. The present disclosure also relates to methods of medical treatment and prophylaxis, particularly cellular immunotherapy.

Abstract: The present invention relates to a process for the preparation of 7-(4.7-diazaspiro[2.5]octan-7-yl)-2-(2.8-dimethylimidazo[1.2-b]pyridazin-6-yl)pyrido[1.2-a]pyrimidin-4-one derivatives useful as pharmaceutically active compounds.